세계의 경구 고형 제제 위탁 생산 시장 보고서

The global demand for Oral Solid Dosage Contract Manufacturing Market is presumed to reach the market size of nearly USD 61.57 BN by 2030 from USD 32.97 BN in 2022 with a CAGR of 8.12% under the study period 2023 - 2030.

The major factors driving the oral solid dosage contract manufacturing market include the prevalence of viral and chronic diseases and increased pharmaceutical goods that can cure diseases. Moreover, additional factors like the widespread usage of pharmaceutical drugs have caused the extensive need for the large-scale production of innovative treatments for patients suffering from various ailments. Major pharmaceutical corporations are progressively outsourcing contract manufacturing as the need for large-scale production increases. As a result, as demand for innovative medicines rises, so will the need for oral solid dose contract manufacturing. In the years to come, higher economic prosperity and greater health awareness are also projected to positively impact market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of oral solid dosage contract manufacturing. The growth and trends of oral solid dosage contract manufacturing industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the oral solid dosage contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Tablets
• Capsules
• Powders
• Granules
• Others (Lozenges, Gummies, Pastilles, Etc.)

By Mechanism

• Immediate-Release
• Delayed-Release
• Controlled-Release

By End-User

• Large-Size Companies
• Medium- & Small-Size Companies
• Others (Startups & Generic Pharmaceutical Companies)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Oral Solid Dosage Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the oral solid dosage contract manufacturing market include Catalent Inc, Lonza Group, Piramal Pharma Solutions, Aenova, Jubilant, Boehringer Ingelheim, AbbVie Contract Manufacturing, Patheon, Recipharm, Next Pharma AB, Siegfried AG, Corden Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ORAL SOLID DOSAGE CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Mechanism
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET ANALYSIS BY PRODUCT TYPE

• 6.1 Overview by Product Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Product Type
• 6.4 Tablets Historic and Forecast Sales by Regions
• 6.5 Capsules Historic and Forecast Sales by Regions
• 6.6 Powders Historic and Forecast Sales by Regions
• 6.7 Granules Historic and Forecast Sales by Regions
• 6.8 Others (Lozenges, Gummies, Pastilles, etc.) Historic and Forecast Sales by Regions

7 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET ANALYSIS BY MECHANISM

• 7.1 Overview by Mechanism
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Mechanism
• 7.4 Immediate-release Historic and Forecast Sales by Regions
• 7.5 Delayed-release Historic and Forecast Sales by Regions
• 7.6 Controlled-release Historic and Forecast Sales by Regions

8 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY END-USER

• 8.1 Overview by End-user
• 8.2 Historical and Forecast Data
• 8.3 Analysis by End-user
• 8.4 Large-size Companies Historic and Forecast Sales by Regions
• 8.5 Medium- & Small-size Companies Historic and Forecast Sales by Regions
• 8.6 Others (Startups & Generic Pharmaceutical Companies) Historic and Forecast Sales by Regions

9 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook Sales Analysis
• 9.2. Introduction Sales Analysis
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE ORAL SOLID DOSAGE CONTRACT MANUFACTURING COMPANIES

• 10.1. Oral Solid Dosage Contract Manufacturing Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF ORAL SOLID DOSAGE CONTRACT MANUFACTURING INDUSTRY

• 11.1. Top 10 Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Catalent Inc
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. Lonza Group
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Piramal Pharma Solutions
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Aenova
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. Jubilant
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. Boehringer Ingelheim
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. AbbVie Contract Manufacturing
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Patheon
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. Recipharm
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments
• 11.12. Next Pharma AB
  • 11.12.1. Company Overview
  • 11.12.2. Company Revenue
  • 11.12.3. Products
  • 11.12.4. Recent Developments
• 11.13. Siegfried AG
  • 11.13.1. Company Overview
  • 11.13.2. Company Revenue
  • 11.13.3. Products
  • 11.13.4. Recent Developments
• 11.14. Corden Pharma
  • 11.14.1. Company Overview
  • 11.14.2. Company Revenue
  • 11.14.3. Products
  • 11.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies